NMDAR1和GABA_A受体的α_1及α_3亚单位在成年猫小脑的定位分布

用免疫组织化学反应及 Nissl染色探讨了 NMDAR1及 GABAA受体α1 和α3亚单位在成年猫小脑皮质及小脑核的定位分布。结果表明 ,NMDAR1免疫反应产物主要分布在 Purkinje细胞胞质和分子层的树突 ,分子层的星形细胞和篮细胞以及颗粒细胞层的颗粒细胞和胶质细胞呈中等强度的阳性反应 ,小脑核的神经元胞质和部分突起着色明显。 GABAA受体的α1 亚单位免疫反应产物主要分布在 Purkinje细胞胞质和树突 ,分子层的星形细胞和胶质细胞呈弱阳性 ,小脑核的神经元阳性反应明显。GABAA 受体的α3亚单位免疫反应产物主要分布在 Purkinje细胞胞质和树突 ,分子层的星形细胞和篮细胞着色明显 ,胶质细胞呈免疫反应弱阳性 ,小脑核神经元及纤维着色明显。在 Purkinje细胞层 NMDAR1、GABAA受体α1 及α3亚单位免疫阳性神经元分别占 Purkinje细胞总数的 80 % ,61% ,88%。结论 :NMDAR1、GABAA受体的α1 及α3亚单位在成年猫小脑具有广泛的分布。这些受体在介导小脑的复杂功能中可能发挥重要的作用。     

Lasting changes in NMDAR1 mRNA level in various regions of cerebral cortex in epileptogenesis of amygdaloid-kindled rat

The involvement of NMDA receptor subunit, NR1, with kindling phenomenon has been reported, but the role of NR1 in epileptogenesis is still unknown. We have examined the expression levels of NR1 mRNA in the cerebral cortices of amygdaloid-kindled rats. Northern blot analysis showed a significant increase in NR1 mRNA expression level in the ipsilateral frontal and temporal cortices at 4 weeks after the last generalized seizure. At the same time, NR1 mRNA decreased in the bilateral piriform cortices. These data suggest that NR1-mediated transmission may have an impact in the neurobiological basis of enduring epileptogenesis.     

Enriched environment has limited capacity for the correction of hippocampal memory-dependent schizoid behaviors in rats with early postnatal NMDAR dysfunction

Pre- and early postnatal stress can cause dysfunction of the N-methyl-d-aspartate receptor (NMDAR) and thereby promote the development of hippocampus memory-dependent schizoid abnormalities of navigation in space, time, and knowledge. An enriched environment improves mental abilities in humans and animals. Whether an enriched environment can prevent the development of schizoid symptoms induced by neonatal NMDAR dysfunction was the central question of our paper. The experimental animals were Wistar rats. Early postnatal NMDAR dysfunction was created by systemic treatment of rat pups with the NMDAR antagonist MK-801 at PD10–20 days. During the development period (PD21–90 days), the rats were reared in cognitively and physically enriched cages. Adult age rats were tested on navigation based on pattern separation and episodic memory in the open field and on auto-hetero-associations based on episodic and semantic memory in a step-through passive avoidance task. The results showed that postnatal NMDAR antagonism caused abnormal behaviors in both tests. An enriched environment prevented deficits in the development of navigation in space based on pattern separation and hetero-associations based on semantic memory. However, an enriched environment was unable to rescue navigation in space and auto-associations based on episodic memory. These data may contribute to the understanding that an enriched environment has a limited capacity for therapeutic interventions in protecting the development of schizoid syndromes in children and adolescents.     

Rats classified as low or high cocaine locomotor responders: A unique model involving striatal dopamine transporters that predicts cocaine addiction-like behaviors

Individual differences are a hallmark of drug addiction. Here, we describe a rat model based on differential initial responsiveness to low dose cocaine. Despite similar brain cocaine levels, individual outbred Sprague-Dawley rats exhibit markedly different magnitudes of acute cocaine-induced locomotor activity and, thereby, can be classified as low or high cocaine responders (LCRs or HCRs). LCRs and HCRs differ in drug-induced, but not novelty-associated, hyperactivity. LCRs have higher basal numbers of striatal dopamine transporters (DATs) than HCRs and exhibit marginal cocaine inhibition of in vivo DAT activity and cocaine-induced increases in extracellular DA. Importantly, lower initial cocaine response predicts greater locomotor sensitization, conditioned place preference and greater motivation to self-administer cocaine following low dose acquisition. Further, outbred Long-Evans rats classified as LCRs, versus HCRs, are more sensitive to cocaine's discriminative stimulus effects. Overall, results to date with the LCR/HCR model underscore the contribution of striatal DATs to individual differences in initial cocaine responsiveness and the value of assessing the influence of initial drug response on subsequent expression of addiction-like behaviors.     

Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine‐binding site of N‐methyl‐D‐aspartate receptor

Sunifiram is a novel pyrrolidone nootropic drug structurally related to piracetam, which was developed for neurodegenerative disorder like Alzheimer's disease. Sunifiram is known to enhance cognitive function in some behavioral experiments such as Morris water maze task. To address question whether sunifiram affects N‐methyl‐D ‐aspartate receptor (NMDAR)‐dependent synaptic function in the hippocampal CA1 region, we assessed the effects of sunifiram on NMDAR‐dependent long‐term potentiation (LTP) by electrophysiology and on phosphorylation of synaptic proteins by immunoblotting analysis. In mouse hippocampal slices, sunifiram at 10–100 nM significantly enhanced LTP in a bell‐shaped dose‐response relationship which peaked at 10 nM. The enhancement of LTP by sunifiram treatment was inhibited by 7‐chloro‐kynurenic acid (7‐ClKN), an antagonist for glycine‐binding site of NMDAR, but not by ifenprodil, an inhibitor for polyamine site of NMDAR. The enhancement of LTP by sunifilam was associated with an increase in phosphorylation of α‐amino‐3‐hydroxy‐5‐methylisozazole‐4‐propionate receptor (AMPAR) through activation of calcium/calmodulin‐dependent protein kinase II (CaMKII) and an increase in phosphorylation of NMDAR through activation of protein kinase Cα (PKCα). Sunifiram treatments at 1–1000 nM increased the slope of field excitatory postsynaptic potentials (fEPSPs) in a dose‐dependent manner. The enhancement was associated with an increase in phosphorylation of AMPAR receptor through activation of CaMKII. Interestingly, under the basal condition, sunifiram treatments increased PKCα (Ser‐657) and Src family (Tyr‐416) activities with the same bell‐shaped dose‐response curve as that of LTP peaking at 10 nM. The increase in phosphorylation of PKCα (Ser‐657) and Src (Tyr‐416) induced by sunifiram was inhibited by 7‐ClKN treatment. The LTP enhancement by sunifiram was significantly inhibited by PP2, a Src family inhibitor. Finally, when pretreated with a high concentration of glycine (300 μM), sunifiram treatments failed to potentiate LTP in the CA1 region. Taken together, sunifiram stimulates the glycine‐binding site of NMDAR with concomitant PKCα activation through Src kinase. Enhancement of PKCα activity triggers to potentiate hippocampal LTP through CaMKII activation. © 2013 Wiley Periodicals, Inc.     

NMDAR/PSD-95/nNOs复合体及其解偶联剂在治疗缺血性卒中的应用

缺血性脑卒中是一种高死亡率、高致残率、高复发率的疾病。目前认为,脑卒中是由各种血管性病因引起的急性或局灶性脑功能障碍,且持续时间超过24 h或引起死亡的临床症候群。随着对脑卒中发病机制的深入研究,其治疗药物也日新月异,该文综合国内外文献,根据NMDAR/PSD-95/nNOs复合体结构特点及其如何在缺血性脑卒中产生病理作用,阐明新型解偶联药物在治疗缺血性卒中的应用前景。     

Movement disorders in children with anti‐NMDAR encephalitis and other autoimmune encephalopathies

Accurate recognition of movement disorder phenomenology may differentiate children with anti‐N‐methyl D‐aspartate receptor (NMDAR) encephalitis, autoimmune basal ganglia encephalitis (BGE), and Sydenham's chorea (SC). Three neurologists blinded to the diagnoses recorded dominant and associated movement disorders seen on videos of 31 patients with anti‐NMDAR encephalitis (n = 10), BGE (n = 12), and SC (n = 9). Stereotypy was only seen in anti‐NMDAR encephalitis (8/10) and not in BGE and SC (P < 0.001). Perseveration was only seen in anti‐NMDAR encephalitis (5/10) and not in BGE and SC (P < 0.001). Akinesia was more commonly seen in BGE (5/12) than in anti‐NMDAR encephalitis (1/10, P = 0.097). Tremor was more commonly seen in BGE (5/12) than in anti‐NMDAR encephalitis (1/10, P = 0.097). Chorea was seen in all groups: anti‐NMDAR encephalitis (4/10), BGE (3/12), and SC (9/9). Likewise, dystonia was seen in all groups: anti‐NMDAR encephalitis (6/10), BGE (7/12), and SC (2/9). Stereotypies or perseveration are suggestive of anti‐NMDAR encephalitis, whereas their absence and the presence of akinesia and tremor is more suggestive of BGE. Chorea and dystonia are least discriminating. © 2014 International Parkinson and Movement Disorder Society     

Neurologic Autoimmunity in the Era of Checkpoint Inhibitor Cancer Immunotherapy

Neurologic autoimmune disorders in the context of systemic cancer reflect antitumor immune responses against onconeural proteins that are autoantigens in the nervous system. These responses observe basic principles of cancer immunity and are highly pertinent to oncological practice since the introduction of immune checkpoint inhibitor cancer therapy. The patient’s autoantibody profile is consistent with the antigenic composition of the underlying malignancy. A major determinant of the pathogenic outcome is the anatomic and subcellular location of the autoantigen. IgGs targeting plasma membrane proteins (eg, muscle acetylcholine receptor -IgG in patients with paraneoplastic myasthenia gravis) have pathogenic potential. However, IgGs specific for intracellular antigens (eg, antineuronal nuclear antibody 1 [anti-Hu] associated with sensory neuronopathy and small cell lung cancer) are surrogate markers for CD8⁺ T lymphocytes targeting peptides derived from nuclear or cytoplasmic proteins. In an inflammatory milieu, those peptides translocate to neural plasma membranes as major histocompatibility complex class I protein complexes. Paraneoplastic neurologic autoimmunity can affect any level of the neuraxis and may be mistaken for cancer progression. Importantly, these disorders generally respond favorably to early-initiated immunotherapy and cancer treatment. Small cell lung cancer and thymoma are commonly associated with neurologic autoimmunity, but in the context of checkpoint inhibitor therapy, other malignancy associations are increasingly recognized.     

平痫冲剂对戊四唑致痫大鼠海马氨基酸类神经递质受体的影响

目的通过免疫组织化学方法分析平痫冲剂对戊四唑（PTZ）致痫大鼠海马氨基酸类神经递质受体的影响,探讨其抗癫痫的作用机理。方法将60只28日龄的Wistar大鼠随机分为正常对照组（A组）、模型组（B组）、苯巴比妥组（c组）及平痫冲剂小（D组）、中（E组）、大（F组）剂量组。除正常对照组外,其余各组大鼠腹腔注射PTZ复制慢性癫痫模型,通过免疫组织化学方法和显微图像分析技术分别检测各组大鼠海马CA1、CA3的谷氨酸受体（NMDARI）和γ-氨基丁酸受体（GABA-ARα1）免疫反应的阳性细胞数（n）、阳性细胞面积比（Aa％）及阳性细胞积分吸光度（IA）。结果与A组比较,B组海马CA1、CA3等部位NMDAR1的n、Aa％上升,IA增加（P〈O．01）;与B组比较,c组及D、E、F组不同部位NMDARI的n、Aa％~-不同程度下降,IA也有不同程度减少（P〈0．05）。同A组比较,B组海马CA1、CA3等部位GABA-ARα,的11、Aa％下降,IA降低（P〈0．01）;与B组比较,C、D、E、F组不同部位GABA—ARα,的n、Aa％都有不同程度增加,IA也有不同程度升高（P〈0．05）。结论平痫冲剂抗癫痫的作用机理可能是通过抑制海马兴奋性神经递质受体NMDAR1的活性与表达,并激活其抑制神经递质受体GABA-ARα,的活性与表达,从而降低大脑皮质的兴奋性,有效抑制癫痫的形成及发展。